<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171986</url>
  </required_header>
  <id_info>
    <org_study_id>E2019367</org_study_id>
    <nct_id>NCT04171986</nct_id>
  </id_info>
  <brief_title>Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis</brief_title>
  <official_title>Mecapegfilgrastim Prevents Prospective, One-arm, Single-center Study of Concurrent Hyperfractionated Chemoradiotherapy With Neutropenia and Radiation Esophagitis in Limited-stage Small Cell Lung Cance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia
      and radiation esophagitis after hyperfractionation in patients with limited-stage small cell
      lung cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of neutrophil radiation esophagitis begins with hyperfractionated chemoradiotherapy.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of 3 and 4 degrees neutropenia within 6 weeks from the start of hyperfractionated radiotherapy</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecapegfilgrastim</intervention_name>
    <description>Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with limited small cell lung cancer diagnosed by histopathology;

          -  ECOG 0-1 points;

          -  Weight ≥ 45 kg;

          -  Age 18-75 years old;

          -  It is expected that at least 2 cycles of EP chemotherapy will be completed as planned;
             once thiophene penicillin is used, chemotherapy should not be re-dosed within 12 days.

          -  Bone marrow hematopoietic function is normal, no bleeding tendency (INR&lt;1.5);

          -  Laboratory tests are subject to: (1) Blood routine examination: Hb≥90g/L; WBC≥4.0×109/
             L; ANC≥2.0×109/L; PLT≥100×109/L. (2) Liver function, biochemical examination: ALT and
             AST≤1.5×ULN; TBIL≤1.5×ULN; Serum creatinine≤1.5×ULN.

          -  According to the researcher's judgment, the test plan can be observed;

          -  Volunteer to participate in this clinical trial, understand the research process and
             be able to sign informed consent in writing.

        Exclusion Criteria:

          -  There are currently uncontrolled infections or systemic antibiotics within 72 hours of
             receiving chemotherapy;

          -  Any abnormal bone marrow hyperplasia and other hematopoietic dysfunction;

          -  Patients who have received bone marrow or hematopoietic stem cell transplantation
             within the past 3 months;

          -  Patients with previous malignant tumors that have not been cured or have brain
             metastases;

          -  Liver function tests Total bilirubin (TBIL), alanine aminotransferase (ALT), and
             aspartate aminotransferase (AST) are &gt;2.5 times the upper limit of normal; if due to
             liver metastasis, the above indicators are &gt;5 times the upper limit of normal;

          -  Renal function test: serum creatinine (Cr) &gt; 1.5 times the upper limit of normal;

          -  Those who are allergic to this product;

          -  suffering from mental or neurological disorders that cannot be matched;

          -  Female patients during pregnancy or lactation; women of childbearing age who refuse to
             receive contraception;

          -  The investigator believes that it is not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning bo Liu, M.D., Ph.D</last_name>
    <phone>15822117216</phone>
    <email>Liuningbo@tjmuch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning bo Liu, MD</last_name>
      <phone>15822117210</phone>
      <email>liuningbo@tjmuch.com</email>
    </contact>
    <contact_backup>
      <last_name>Ping Wang, MD</last_name>
      <phone>18622221112</phone>
      <email>wangping99999@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>HHPG-19K</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

